Drug Profile
Sivelestat
Alternative Names: EI 546; Elaspol; LY 544349; ONO 5046; ONO 5046 . Na; ONO 5406; ONO 5406 . NaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Class Amino acids; Antiasthmatics; Antineoplastics; Antirheumatics; Sulfonamides
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute lung injury
- Discontinued Adult respiratory distress syndrome; Lung disorders; Lung transplant rejection; Non-small cell lung cancer; Pulmonary fibrosis; Respiratory insufficiency; Rheumatoid arthritis
Most Recent Events
- 13 May 2010 Discontinued - Phase-II for Respiratory insufficiency in Japan (unspecified route)
- 30 Oct 2009 Sivelestat is still in phase II trials for respiratory insufficiency in Japan
- 20 Dec 2006 Launched for Acute lung injury in South Korea (IV)